Among the studies in advanced NSCLC that we identified, only pembrolizumab plus chemotherapy (KEYNOTE-189 [NSQ NSCLC]) reported an OS HR and 95% CI that were below 1.0 among patients with PD-L1 <1% and similar to that observed in the subgroups with PD-L1 1 - 49% and ≥50% (Tables 3, 4, Figures 4, 5, 6, 7). The gene discussed is CD274; the disease is non-small cell lung carcinoma.